In short
This article summarizes clinical trials evaluating the use of inotuzumab ozogamicin, an antibody-drug conjugate, for treating various types of leukemia and lymphoma. The drug targets CD22-positive cancer cells and has shown promise in treating relapsed or refractory acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma. Clinical trials have assessed its efficacy, safety, and optimal dosing when used alone or in combination with other therapies.
At a glance
- Drug Name
- Inotuzumab ozogamicin (also known as CMC-544)
- Drug Type
- Antibody-drug conjugate targeting CD22-positive cells
- Main Indications
- Relapsed/refractory acute lymphoblastic leukemia (ALL), Non-Hodgkin's lymphoma
- Administration
- Intravenous infusion, typically in cycles
- Common Dosing
- 1.8 mg/m2 per cycle, often given as 3 weekly doses
- Key Efficacy Measures
- Complete remission rates, minimal residual disease negativity, progression-free survival, overall survival
- Safety Considerations
- Hematological toxicities, liver toxicity, veno-occlusive disease
- Combination Therapies
- Studied with rituximab and as part of various treatment regimens
- Patient Populations
- Adults with relapsed/refractory ALL, elderly patients, post-transplant patients
- Ongoing Research
- Optimal dosing, efficacy in different subgroups, use in maintenance therapy
What is Inotuzumab Ozogamicin?
Inotuzumab ozogamicin is a medication used to treat certain types of blood cancers. It is also known by the brand name Besponsa and was previously called CMC-544 during its development. Inotuzumab ozogamicin is a type of drug called an antibody-drug conjugate. This means it combines an antibody (a protein that targets specific cells) with a chemotherapy drug.
How Does Inotuzumab Ozogamicin Work?
Inotuzumab ozogamicin works by targeting a protein called CD22, which is found on the surface of certain blood cancer cells. The antibody part of the drug attaches to CD22, allowing the chemotherapy part to enter and kill the cancer cells. This targeted approach aims to destroy cancer cells while minimizing damage to healthy cells.
What Conditions Does Inotuzumab Ozogamicin Treat?
Inotuzumab ozogamicin is primarily used to treat blood cancers, including:
- Acute Lymphoblastic Leukemia (ALL): This is a fast-growing cancer of the white blood cells. Inotuzumab ozogamicin is used in adults with B-cell ALL that has come back after treatment (relapsed) or has not responded to initial treatment (refractory).
- Non-Hodgkin's Lymphoma (NHL): This is a group of blood cancers that start in white blood cells called lymphocytes. Inotuzumab ozogamicin has been studied in various types of NHL, including diffuse large B-cell lymphoma and follicular lymphoma.
How is Inotuzumab Ozogamicin Given?
Inotuzumab ozogamicin is given as an intravenous (IV) infusion, which means it's delivered directly into a vein. The typical treatment schedule is:
- One dose given weekly for 3 weeks
- Each 3-week period is considered one treatment cycle
- Patients may receive up to 6 cycles of treatment
The exact dose and schedule may vary depending on the specific condition being treated and how well the patient tolerates the medication.
How Effective is Inotuzumab Ozogamicin?
Clinical trials have shown promising results for inotuzumab ozogamicin in treating blood cancers:
- In patients with relapsed or refractory ALL, inotuzumab ozogamicin led to complete remission (disappearance of all signs of cancer) in a significant number of patients.
- For patients with NHL, studies have shown that inotuzumab ozogamicin can help achieve complete or partial responses (significant reduction in cancer).
- Some trials have also looked at using inotuzumab ozogamicin after stem cell transplantation to help prevent the cancer from coming back.
What Are the Side Effects of Inotuzumab Ozogamicin?
Like all medications, inotuzumab ozogamicin can cause side effects. Some of the most common or serious side effects include:
- Blood-related side effects: Low blood cell counts (anemia, neutropenia, thrombocytopenia) which can increase the risk of infections, fatigue, and bleeding.
- Liver problems: Including a serious condition called veno-occlusive disease (VOD) or sinusoidal obstruction syndrome (SOS), which can damage the liver.
- Infusion-related reactions: Symptoms like fever or chills that can occur during or shortly after receiving the medication.
- Gastrointestinal issues: Such as nausea, vomiting, or abdominal pain.
- Fatigue: Feeling very tired is a common side effect.
Patients should discuss all potential side effects with their healthcare provider before starting treatment.
Ongoing Research on Inotuzumab Ozogamicin
Researchers continue to study inotuzumab ozogamicin to understand how to use it most effectively. Some areas of ongoing research include:
- Using inotuzumab ozogamicin in combination with other cancer treatments.
- Exploring its use in pediatric patients with ALL.
- Investigating different dosing schedules to improve efficacy and reduce side effects.
- Studying its effectiveness in patients with minimal residual disease (very low levels of cancer cells remaining after initial treatment).
These ongoing studies aim to expand our understanding of how to best use inotuzumab ozogamicin to help patients with blood cancers.